In healthcare, we are fortunate to have access to code that analyzes data and provides us with customer insights. As marketers, we can now understand these individual customers better than ever before. We know what we need and want to do when it comes to reaching them. But what does all that power and possibility do for them?
HBA Global presents Virtual Professionals: Visibility & Trajectory in a Virtual Career (Series Purchase – 3 Webinars)
Are you in sales, working out in the field or working remotely or virtually, away from the home office? Then these webinars are for you! Join the HBA for a three-part webinar series that takes on core challenges that virtual workers – both field-based and remote – face in their careers: gaining and improving visibility; career planning; and building relationships with mentors, sponsors and coaches.
Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.
Johnson & Johnson and the company’s DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company’s metal-on-metal hip implants.
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Maryland charged Insys Therapeutics Inc. with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.
Medtronic Plc agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said.